All Randomized Pediatric Patients to Continue in the Single-Blind Extension ...
(PR-inside.com) Continuation of treatment with blinded doses of crofelemer in the extension phase of the trial will support company's plans to file an NDA in mid-2027 for MVID, an ultrarare pediatric disease SAN FRANCISCO, CA / ACCESS Newswire / September 10, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family com…
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


